UK markets close in 3 hours 36 minutes

Valneva SE (0OB3.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
5.34-0.34 (-5.92%)
As of 12:25PM BST. Market open.
Full screen
Previous close5.68
Open5.45
Bid0.00 x 0
Ask0.00 x 0
Day's range5.20 - 5.47
52-week range5.20 - 5.47
Volume12,002
Avg. volumeN/A
Market cap4.792M
Beta (5Y monthly)0.94
PE ratio (TTM)N/A
EPS (TTM)-0.71
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Valneva Announces Launch of Approximately $40 Million in a Proposed Global Offering of American Depositary Shares and Ordinary Shares

    Saint Herblain (France), September 28, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (the “Company”), a specialty vaccine company, today announced its intention to issue and sell, subject to market conditions, approximately $40 million of its ordinary shares in a global offering to specified categories of investors comprised of (i) a public offering of its American Depositary Shares (“ADSs”), each representing two ordinary shares, in the United States (the “U.S. Offering”) and (ii) a con

  • Zacks

    Valneva (VALN) Stock Down 66% in the Past 6 Months: Here's Why

    Valneva's (VALN) COVID-19 vaccine looks promising, but the European Commission's revised advance purchase agreement jeopardizes its COVID-19 vaccine program.

  • Globe Newswire

    Valneva Provides Further Update on its COVID-19 Activities

    Saint-Herblain (France), September 26, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced a further update on its COVID-19 vaccine activities. The Company had previously communicated that it would invest in further development of a potential second-generation COVID-19 vaccine only if it received the necessary funding or commitments to such funding during the third quarter of 20221. The Company is in active discussions with a prospective partner fo